Adler Elizabeth C, Levine Emma H, Ibarra Allison N, Boparai Eshandeep S, Hung Yun-Yi, McCrary Quincy D, Lee Jeffrey K
Department of Gastroenterology, Kaiser Permanente, San Francisco, San Francisco, California, USA.
Department of Gastroenterology, University of Chicago, Chicago, Illinois, USA.
Neurogastroenterol Motil. 2025 Apr 3:e70037. doi: 10.1111/nmo.70037.
Gut-directed hypnotherapy has been shown to be an effective treatment for irritable bowel syndrome, but prior studies have been small with variable delivery modalities. This systematic review and meta-analysis investigates the efficacy of gut-directed hypnotherapy for irritable bowel syndrome (IBS) symptoms and the impact of delivery characteristics.
PubMed, Embase, and Web of Science were searched. Titles and abstracts, then full text articles, were screened for inclusion criteria. Studies were extracted and assessed for bias using the Cochrane Collaboration risk-of-bias tool. A meta-analysis was performed to assess the impact of gut-directed hypnotherapy on global IBS symptoms and pain. A sub-group analysis was conducted to assess the impact of gut-directed hypnotherapy delivery characteristics on IBS-related outcomes.
Twelve studies in 11 papers met inclusion criteria, involving 1158 patients with IBS. Eight studies provided continuous measures sufficient for meta-analysis. On systematic review, all 12 studies found gut-directed hypnotherapy to be superior to the comparator; nine were statistically significant. On meta-analysis, gut-directed hypnotherapy improved global IBS symptoms (SMD 0.73 [-0.09-1.55], I 93%). Gut-directed hypnotherapy with high-volume delivery and gut-directed hypnotherapy delivered in groups showed statistically significant improvement in global IBS symptoms (SMD 0.56 [0.29-0.83], I 0%; SMD 0.41 [0.05-0.77], I 61%). Gut-directed hypnotherapy also significantly improved pain more than its comparator groups (SMD 0.25 [0.01-0.49], I 17%).
Gut-directed hypnotherapy may improve global symptoms of IBS. In particular, GDH improved pain symptoms compared to other standard IBS interventions. GDH delivered in groups was effective at reducing global IBS symptoms compared to standard interventions.
肠道定向催眠疗法已被证明是治疗肠易激综合征的有效方法,但先前的研究规模较小,且治疗方式多样。本系统评价和荟萃分析旨在研究肠道定向催眠疗法对肠易激综合征(IBS)症状的疗效以及治疗特征的影响。
检索了PubMed、Embase和Web of Science数据库。先筛选标题和摘要,再筛选全文文章以确定纳入标准。提取研究并使用Cochrane协作偏倚风险工具评估偏倚。进行荟萃分析以评估肠道定向催眠疗法对IBS整体症状和疼痛的影响。进行亚组分析以评估肠道定向催眠疗法的治疗特征对IBS相关结局的影响。
11篇论文中的12项研究符合纳入标准,涉及1158例IBS患者。8项研究提供了足以进行荟萃分析的连续测量数据。在系统评价中,所有12项研究均发现肠道定向催眠疗法优于对照疗法;9项具有统计学意义。在荟萃分析中,肠道定向催眠疗法改善了IBS的整体症状(标准化均数差0 . 73[-0 . 09 - 1 . 55],I²93%)。大容量给药的肠道定向催眠疗法和分组进行的肠道定向催眠疗法在IBS整体症状方面显示出统计学显著改善(标准化均数差0 . 56[0 . 29 - 0 . 83],I²0%;标准化均数差0 . 41[0 . 05 - 0 . 77],I²61%)。肠道定向催眠疗法在改善疼痛方面也显著优于对照疗法(标准化均数差0 . 25[0 . 01 - 0 . 49],I²17%)。
肠道定向催眠疗法可能改善IBS的整体症状。特别是,与其他标准的IBS干预措施相比,肠道定向催眠疗法改善了疼痛症状。与标准干预措施相比,分组进行的肠道定向催眠疗法在减轻IBS整体症状方面有效。